Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer

Advanced colorectal cancer (ACRC)

To determine complete resection (R0), response rate, time to progression (TTP) and
overall survival (OS) in patients with non-resectable ACRC after being treated with
neoadjuvant irinotecan-based chemotherapy.

Official Title

Conditions

Study Type

Retrospective analysis

Study Design

Further Details

Treatment Details:Irinotecan 250 mg/m2 i.v. (1h) d1UFT 300 mg/m2 p.o. d1-14Leucovorin 45 mg/d p.o d1-14Every 3 weeksorFOLFIRIIrinotecan: 180 mg/m2 i.v. d15-FU: 400 mg/m2 i.v. bolus5-FU: 2400 mg/m2 cont. inf (46h)Leucovorin: 200 mg/m2 i.v. d1Every 2 weeksAdministered until non-resectable disease was converted to resectability, or diseaseprogression, unacceptable toxicity or patient withdrawal or for a maximum of 12cycles (in complete responders).Efficacy:CR: 6 (17%)PR: 15 (41%)SD: 7 (20%)Progression: 8 (22%)Med. time to response: 2.2 monthsR0 resection: 8 (22%)Med TTP: 10 moMed OS: 38 moTolerability: Toxicity was in accordance to previous reported irinotecan-based chemotherapy regimens. There were no toxic deaths reported.Conclusions from the Authors: This retrospective study showed a high resectability rate, and a prolonged TTP andOS in patients with ACRC after induction treatment with irinotecan-basedchemotherapy. Both toxicity profile and postoperative complications were acceptable.Nevertheless, the definitive role of irinotecan as induction treatment should beconfirmed in future clinical trials.Conclusions from Baxter Oncology: There is no information regarding the two different regimens.

Study Start

Eligibility & Criteria

Histologically confirmed ACRC; initially non-resectable disease; induction treatmentwith irinotecan-based chemotherapy; age > 18 years; normal renal, hepatic and bonemarrow functions; no previous chemotherapy agent on metastatic setting; previoushistory of cancer (except for resolved carcinoma of the cervix uteri or basal cutaneouscarcinoma).

Total Enrolment

36 (13 FOLFIRI)

Contact Details

Anti-Cancer Drugs 16 (2005): 31-38Baxter